INNOVATION THROUGH COLLABORATION

TECHNOLOGY TRANSFER OFFICE
8727 W. THIRD ST., SUITE 203
LOS ANGELES, CA 90048
PHONE: +1.310.423.0326
CStechtransfer@cshs.org
cedars-sinai.edu/international-program
Cedars-Sinai contributes to the advancement of medicine worldwide through international collaborations that result in dramatic improvements in patient care. As part of Cedars-Sinai’s charitable mission of education, the International Program was established in 2000 to provide operational support, education and strategic direction for the biotechnology research and development activities for hospitals and academic research institutions in Central and Eastern Europe.

Through collaboration, the International Program aims to work together with its global partners to develop and enhance each other’s technology transfer efforts with the common goal of maximizing technologies for the benefit of patients worldwide.
The Technology Transfer Office protects and supports the commercialization of Cedars-Sinai’s discoveries and technologies. Managing over 50 licenses that generate more than $30 million annually, its diverse portfolio includes therapeutics, devices, diagnostics and software.
From its origins as a technology transfer educational program in Eastern Europe, the International Program has matured into a full-fledged division of the Technology Transfer Office with an expanded network of nearly 50 active partners from around the world, including those in Hong Kong, Singapore, Spain, the United Kingdom and Uruguay. These international activities allow Cedars-Sinai to:

• access global markets;
• find resources to develop technologies; and
• identify opportunities for investment or licensing.

We are always seeking new partners who share our drive to advance scientific and medical technologies.

Our areas of interest include:

• Oncology
• Neuroscience
• Gastrointestinal disorders
• Cardiovascular diseases
• Regenerative medicine
Biomarkers and assays are crucial to achieving earlier and more accurate diagnoses of disease. The Technology Transfer Office established 3rd Street Diagnostics, a business unit within Cedars-Sinai, to develop and commercialize diagnostic, prognostic and other personalized medicine tests.

International partners collaborate with 3rd Street Diagnostics to commercialize promising biomarker discoveries and related new inventions in the United States and other foreign markets.

The Technology Transfer Office is particularly interested in facilitating molecular diagnostic technologies that utilize:

- deoxyribonucleic acid (DNA) sequencing;
- ribonucleic acid (RNA) expression; or
- single and multiplex, protein-based assays and cell-based tests.
Cedars-Sinai has entered into a global exclusive partnership with Techstars to create a healthcare accelerator to enable today’s top technology entrepreneurs to grow their businesses with funding, support and mentorship provided by Cedars-Sinai’s leadership team.

Companies selected for the Cedars-Sinai Accelerator enter an immersive 3-month program, in which they are surrounded by top clinical leaders and subject matter experts who guide the startups in market positioning, customer acquisition, product development and overall growth.

At the program’s end, the participating startups showcase their work at a demonstration day attended by investors and industry executives. The inaugural class featured 11 companies, all of which signed commercial agreements with Cedars-Sinai.
Established in 1902, Cedars-Sinai Medical Center in Los Angeles, California, has four charitable missions:

- Provide the highest quality patient care
- Expand scientific and medical knowledge through research
- Educate healthcare professionals for the future
- Improve the health status of the community

- 886 Licensed Beds
- 254,668 Patient Days
- 751,920 Outpatient Visits
- 49,690 Admissions
- 89,371 Emergency Visits
- 1,519 Research Projects
- 12,057 Full-Time Employees
- 2,156 Physicians on Medical Staff
- 473 Enrolled Residents and Fellows
Our team is committed to having every invention and discovery from both our own researchers and international partners reach its full potential. To support these activities, we have assembled a diverse team covering the entire spectrum of the technology transfer process.

**JAMES D. LAUR**  
*Vice President for Legal and Technology Affairs*  
Mr. Laur has been a member of Cedars-Sinai’s Legal Affairs Department since 1991 and is the institution’s senior intellectual property counsel. Since 1994, he has played a leadership role in Cedars-Sinai’s Technology Transfer Office, which has earned more than $180 million in royalty income from its licensing program in the past 10 years to support Cedars-Sinai’s research enterprise.

**KRISTIN A. MARTINEZ**  
*Associate Director, International Program*  
Ms. Martinez leads the international activities of Cedars-Sinai’s Technology Transfer Office by identifying, directing and implementing projects with the office’s partners around the world.

**NIRDESH K. GUPTA, PhD**  
*Director, IP Portfolio Management and Licensing*  
Dr. Gupta leads a team of IP portfolio and licensing professionals involved in the commercialization of Cedars-Sinai’s intellectual property.

**ALEXANDER Y. CHAI**  
*Assistant Legal Counsel, Technology Transfer*  
Mr. Chai provides legal services to the Technology Transfer Office, with a focus on corporate transactions and intellectual property law.

**JANNY L. HSU**  
*International Relations Associate*  
Ms. Hsu provides oversight, development, maintenance and support for the International Program and its global collaborators.

**DAVID L. THOMAS**  
*Consultant, International Program*  
Located in Bangkok, Thailand, Mr. Thomas is our point of contact for our partners in the Asia-Pacific region.